185 related articles for article (PubMed ID: 20875545)
1. Towards a cure for chronic myeloid leukemia: are we there yet?
Cortes J
Semin Hematol; 2010 Oct; 47(4):299-301. PubMed ID: 20875545
[No Abstract] [Full Text] [Related]
2. 3. Imatinib therapy in chronic myelogenous leukemia.
Jinnai I
Intern Med; 2007; 46(2):95-7. PubMed ID: 17220607
[No Abstract] [Full Text] [Related]
3. Pretreatment with IFN-α increases resistance to imatinib mesylate in patients with chronic myelocytic leukemia.
Xiao Y; Hu HH; Wang HX; Zhu XJ; Zou P; Chen ZC; Zhong ZD; Li WM; You Y
Acta Pharmacol Sin; 2012 Jul; 33(7):979-80. PubMed ID: 22684027
[No Abstract] [Full Text] [Related]
4. Chronic myeloid leukemia. Introduction.
Frame D
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S2-3. PubMed ID: 18056928
[No Abstract] [Full Text] [Related]
5. Part II: management of resistance to imatinib in chronic myeloid leukaemia.
Apperley JF
Lancet Oncol; 2007 Dec; 8(12):1116-1128. PubMed ID: 18054881
[TBL] [Abstract][Full Text] [Related]
6. Is telomerase a player in chronic phase chronic myeloid leukemia, disease progression and imatinib resistance?
White DL
Leuk Lymphoma; 2008 Jun; 49(6):1022-3. PubMed ID: 18452091
[No Abstract] [Full Text] [Related]
7. Imatinib mesylate.
Am J Health Syst Pharm; 2001 Dec; 58(23):2241-2. PubMed ID: 11765724
[No Abstract] [Full Text] [Related]
8. Targeted chronic myeloid leukemia therapy: Seeking a cure.
Fausel C
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance.
Bixby D; Talpaz M
Hematology Am Soc Hematol Educ Program; 2009; ():461-76. PubMed ID: 20008232
[TBL] [Abstract][Full Text] [Related]
10. [Chronic myeloid leukemia 2008].
Cervantes F
Med Clin (Barc); 2008 Nov; 131(17):658-9. PubMed ID: 19087793
[No Abstract] [Full Text] [Related]
11. Bcr-Abl inhibition as a modality of CML therapeutics.
Buchdunger E; Matter A; Druker BJ
Biochim Biophys Acta; 2001 Aug; 1551(1):M11-8. PubMed ID: 11553417
[No Abstract] [Full Text] [Related]
12. Mutational analysis and overcoming imatinib resistance in chronic myeloid leukemia with novel tyrosine kinase inhibitors.
Mauro MJ
Curr Treat Options Oncol; 2007 Aug; 8(4):287-95. PubMed ID: 18157514
[No Abstract] [Full Text] [Related]
13. STI571 (glivec-tm): a new paradigm for the development of innovative therapies in onco-hematology?
Gambacorti C
Tumori; 2001; 87(6):S10-2. PubMed ID: 11989608
[No Abstract] [Full Text] [Related]
14. Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia.
Giles FJ; Cortes JE; Kantarjian HM
Curr Mol Med; 2005 Nov; 5(7):615-23. PubMed ID: 16305488
[TBL] [Abstract][Full Text] [Related]
15. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
Walz C; Sattler M
Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
[TBL] [Abstract][Full Text] [Related]
16. Treatment options for chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplant.
Angstreich GR; Smith BD; Jones RJ
Curr Opin Oncol; 2004 Mar; 16(2):95-9. PubMed ID: 15075898
[TBL] [Abstract][Full Text] [Related]
17. New directions in the treatment of patients with chronic myeloid leukemia: introduction.
Baccarani M
Semin Hematol; 2009 Apr; 46(2 Suppl 3):S1-4. PubMed ID: 19621542
[No Abstract] [Full Text] [Related]
18. Complete cytogenetic and molecular response to treatment with imatinib mesylate for philadelphia chromosome positive acute myeloid leukemia with multilineage dysplasia.
Ueda K; Horiike S; Zen K; Misawa S; Taniwaki M
Leuk Lymphoma; 2006 Sep; 47(9):1967-9. PubMed ID: 17065015
[No Abstract] [Full Text] [Related]
19. What is new in chronic myeloid leukaemia?
Heaney NB; Holyoake TL
Scott Med J; 2007 Feb; 52(1):36-41; quiz 42, 58. PubMed ID: 17373424
[TBL] [Abstract][Full Text] [Related]
20. A Bcr/Abl kinase antagonist for chronic myelogenous leukemia: a promising path for progress emerges.
Sausville EA
J Natl Cancer Inst; 1999 Jan; 91(2):102-3. PubMed ID: 9923844
[No Abstract] [Full Text] [Related]
[Next] [New Search]
